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1. Introduction 
Over the past several decades stem cell therapy has been characterized as having the 
potential to dramatically change the treatment of human disease. Impact of such therapy on 
pulmonary disorders remains unknown. A lack of evidence for a function of exogenous cells 
in lung repair limits our ability to proceed into clinical trials. Therefore we must rely on 
personal experience and case series to better understand the clinical effects of stem cell 
therapy in pulmonary disease. In this report, we discuss four patients with common 
pulmonary diseases who were treated with the direct infusion of peripherally harvested 
autologous stem cells into the pulmonary arteries. Although these four patients were 
followed by Mayo Clinic, the procedure was performed by Regenocyte Therapeutic, a 
privately owned and operated Florida-based enterprise. The procedure is not approved by 
the United States Food and Drug Administration. In addition, it was not performed in the 
context of an approved clinical trial. Each of the patients in this series independently 
pursued and personally paid for this experimental and controversial treatment. Since the 
practice is not approved in the United States, the stem cell infusion was performed at the 
Centro Otorrino Laringologia Hospital in Santo Domingo, Dominican Republic. This report 
summarizes the clinical experience of these patients based on unrelated clinical assessments 
at the Mayo Clinic performed both before and after the procedure.. 
2. Case 1 
2.1 Clinical history and course 
A 44 year-old Caucasian man and former smoker (38 pack years, quit 2004) presented for 
evaluation in December 2006 for symptoms of progressive dyspnea (World Health 
Organization (WHO) functional class III), fatigue, and presyncopal spells. His past medical 
history was significant for mild chronic obstructive pulmonary disease (COPD) and 
pulmonary hypertension (PH) diagnosed in 2004, with right heart catheterization (RHC) 
revealing a mean pulmonary artery pressure (MPAP) of 37 mmHg. Additional PH risk 
factors included obesity (BMI 33.2), and mild obstructive sleep apnea. The patient had 
recently started sildenafil (25mg dose) on an as needed basis and reported some reduction in 
dyspnea after each use.  
His laboratory evaluation at Mayo Clinic was normal except for an elevated hemoglobin 
(17.7 mg/dL). He was hypoxic on room air (pH 7.4, PaO2 49, PaCO2 33, SaO2 90%), and his 
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pulmonary function test (PFT) revealed mild obstruction with a reduction in diffusing 
capacity for carbon monoxide (DLCO) (Table 1). High-resolution computed tomography 
scan of the chest showed diffuse emphysema. The electrocardiogram was normal and the 
contrast echocardiogram (ECHO) demonstrated mild PH with a right ventricular systolic 
pressure (RVSP) of 49 mmHg and MPAP 31 mmHg. There was mild left-ventricular 
hypertrophy but right-ventricular (RV) size and function were normal with an estimated 
right atrial pressure (RAP) of 5 mmHg. There was no shunt identified (Table 2). A 
ventilation-perfusion (V/Q) lung scan excluded chronic thromboembolic disease (CTED). 
The patient achieved 519 meters in the six-minute walk test (6MWT) performed on 2 liters 
per minute (lpm) oxygen with a nadir saturation of 84%. Overnight oximetry on room air 
demonstrated a low baseline saturation (mean of 87%) and no significant sleep-disordered 
breathing.  
The patient underwent a repeat RHC with cardiopulmonary exercise testing (CPX). The 
RHC revealed mild PH at rest that worsened significantly with exercise (MPAP increased 
from 30 to 58 mmHg) (Table 3). The maximal oxygen consumption was 15.7 mlO2/kg/min 
with an inadequate increase in stroke volume with exercise. Pulmonary arterial vasodilator 
trial revealed no significant response to intravenous epoprostenol. 
His PH was classified as WHO diagnostic group 3 (Simmoneau 2009); therefore, regular 
use of adequate oxygen was recommended. He also started tiotropium inhaler. In 
addition he was instructed to take sildenafil regularly at 20mg three times daily (Alp 
2006). Over the next 9 months the patient reported some improvement; however, he 
remained dyspneic with minimal exertion. Objective measures of his PH remained stable 
(Table 2). Sildenafil use had ceased and he remained non-compliant with oxygen, using it 
only at night or when significantly dyspneic. He was evaluated for possible lung 
transplantation but was not felt to be a good candidate due to noncompliance and his 
body mass index. The recommendations were for weight loss and improved compliance 
with his medical regimen.  
In November 2007, he was seen in follow-up and was again counseled to be more compliant 
with oxygen and to restart sildenafil at 20mg three times daily. The patient had been seen by 
a cardiologist outside our institution for intermittent chest pain and palpitations and had 
been initiated on diltiazem 180mg daily.  
After exploring alternative therapies at a private facility, the patient had blood collected for 
possible stem cell therapy. On March 4, 2008 he traveled to the Dominican Republic where 
he received multiple infusions, of what was reported to be the harvested stem cells, directly 
into the pulmonary arteries.  
Shortly after the infusion, he reported feeling like "Superman," running 1 to 2 hours in the 
first few days. By his report, his room air saturations rose to 99% at 2 weeks, but 
deteriorated subsequently. Other perceived benefits included decreased fatigue, chest pain, 
palpitations, and leg pain and even improved vision and mental acuity. His symptomatic 
improvements persisted at subsequent visits despite becoming more sedentary and gaining 
4.5 kg. Notably, he had become more compliant with the use of oxygen to about 3 lpm by 
nasal cannula at rest. 
Objectively, there were also improvements noted in his 6MWT and in the 
echocardiographic estimates of his pulmonary pressures. (Table 2) These improvements 
were sustained at repeated follow-ups. However, the oxygen requirement remained 8 to 
15 lpm with exertion.  
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During his evaluation in March 2010, the patient reported that many of the initial subjective 
improvements had waned. Overall his objective measures remained relatively stable. (Table 2)  
He had a repeat RHC demonstrating mild resting but severe exercise induced PH (Table 3).  
3. Case 2 
3.1 Clinical history and course 
A 78 year-old Caucasian man presented with dyspnea on exertion (WHO functional class II). 
He had smoked cigars for 19 years and quit 20 years ago. He was diagnosed with moderate 
COPD and was treated with inhaled bronchodilators. A few months prior to his 
presentation at Mayo Clinic, an extensive evaluation including a RHC, a V/Q scan and a 
pulmonary arteriogram demonstrated PH due to CTED. Those studies were reviewed and 
felt to be conclusive. His medications included hydrochlorothiazide, furosemide, and 
warfarin. A PFT demonstrated moderate obstruction, air trapping, a reduced DLCO, and 
oxygen desaturation with exercise (Table 1). The 6MWT and ECHO results are reported in 
Table 2. Arterial blood gas on room air was:  pH 7.47, PaO2 67, PaCO2 37; and the BNP was 
178 pg/mL. Cardiac MRI revealed RV enlargement and hypertrophy with a reduced RV 
ejection fraction to 27%. A repeat RHC was performed, and it was felt the PH was multi-
factorial secondary to COPD, CTED, and mild pulmonary venous hypertension (Table 3).   
Given the patient’s age, minimal symptoms, multiple mechanisms for his PH, and his co-
morbidities, he was considered a high risk for pulmonary endarterectomy, and the patient 
elected for conservative therapy. An inferior vena cava filter was placed and life-long anti-
coagulation was recommended. In addition, supplemental oxygen with exercise and 
sildenafil 20 mg three times daily (Reichenberger 2007) were initiated. 
Six-months later, there was a slight improvement in the 6MWT (Table 2). He was now 
requiring increasing oxygen to maintain saturations at rest (1.5 lpm) and during exertion. 
Given persistently elevated right-heart pressures and RV enlargement and hypokinesis, 
bosentan was added to his regimen. Eight months after adding bosentan, he continued to 
show improvement in the 6MWT but the ECHO was unchanged. Oxygen needs continued 
to increase, now requiring 2 lpm at rest and 15 lpm for the 6MWT (Table 2). 
Three months later, he underwent adult stem infusion. This date corresponded to 18 months 
on sildenafil 20 mg three times daily and 12 months on bosentan at full dose. One week after 
the harvest, he traveled to Santo Domingo for the infusion into his pulmonary arteries via a 
pulmonary artery catheter at Centro Otorrino Laringologia Hospital. Repeat ECHO one 
month later showed a RVSP of 55 mmHg which was exactly the same as his baseline value 
one month prior to the infusion. Another ECHO performed by Regenocyte Therapeutics 
three months after the stem cell infusion demonstrated a RVSP 41 mmHg. A PFT four 
months after stem cell infusion was essentially unchanged (Table 1).  
The patient was seen in follow up at Mayo Clinic approximately 5 and 12 months after his 
stem cell infusion. He stated that he felt neither better nor worse after his stem cell treatment 
and was on 3 lpm oxygen to maintain an adequate resting saturation. His objective 
assessment showed some benefit at 5 months. That benefit had waned one year after stem 
cell infusion. His treatment regimen included diuretics, warfarin, sildenafil 20 mg three 
times daily, bosentan 125 mg twice daily (Jais 2008) and oxygen. He has also been regularly 
participating in a formal pulmonary rehabilitation program. No changes were made in his 
medical regimen. 
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Legend: Pulmonary function test results, oxygenation and modified Borg dyspnea score data on four 
patients who had pulmonary artery stem cell infusion. Key:  FEV1 – Forced Expiratory Volume in One 
Second, FVC – Forced Vital Capacity, TLC – Total Lung Capacity, RV – Residual Volume, DLCO – 
Diffusing Capacity of Carbon Monoxide 
* Percent Predicted. **Test performed on oxygen. ***See Table 2. N/A – Not Available 
Table 1. Pulmonary Function and Six-Minute Walk Testing- Pre and Post Stem Cell Infusion 
www.intechopen.com
 
Autologous Stem Cell Infusion for Treatment of Pulmonary Disease 
 
509 
 
Legend:  Brain natriuretic peptide levels, WHO functional class (1 to 4 scale), six-minute walk distances 
with modified Borg dyspnea score and echocardiography results on Cases 1 and 2 who had pulmonary 
artery stem cell infusion. Key:  BNP – Brain Natriuretic Peptide, WHO – World Health Organization, 
Borg Score – Modified Borg Dyspnea Score on a scale of 0 to 10, Sa02 – Oxygen Saturation, FIO2 – 
Fraction of Inspired Oxygen, RAP – Right Atrial Pressure, TR – Tricuspid Regurgitant (peak), RVSP – 
Right Ventricular Systolic Pressure, MPAP – Mean Pulmonary Artery Pressure, RV – Right Ventricle, 
Normal and Mild describe degree of enlargement and ventricular dysfunction 
* Unable to estimate due to incomplete tricuspid regurgitant jet 
Table 2. Cardiopulmonary Data for Cases 1 and 2 
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RAP 
(mmHG)
PAP 
(mmHG)
MPAP 
(mmHg)
PAOP 
(mmHg)
CO/CI 
(L/min, 
L/min/m2)
PVR 
(dyne sec 
cm-5) 
Vasodila-
tor 
Response
MPAP During 
Exercise 
(mmHg) 
Case 
1 
Baseline 
1/2007 4 45/25 30 12 5.1/2.1 282 No 58 
 
Follow-up 
3/2010 6 44/20 28 14 8.3/3.3 135 No 70 
Case 
2 
Baseline 
10/2007 11 85/34 51 16 5.8/3.2 478 No N/A * 
 Follow-up NOT DONE       
Legend: Hemodynamic data from right heart catheterization on Cases 1 and 2. Key:  RAP – Right Atrial 
Pressure, PAP – Pulmonary Artery Pressure, MPAP – Mean Pulmonary Artery Pressure, PAOP – 
Pulmonary Artery Occlusion Pressure, CO – Cardiac Output, CI – Cardiac Index, PVR – Pulmonary 
Vascular Resistance 
* Exercise study not performed 
Table 3. Baseline and Post Stem Cell Transfusion Right Heart Catheter Data 
4. Case 3 
4.1 Clinical history and course 
A 66-year-old Caucasian man presented in January of 2009 with symptoms of worsening 
dyspnea on exertion. Patient had a past medical history of hypertension and transient 
ischemic attacks. His pulmonary history dates back to 2002 at which time he was told to 
have scarring of his lungs. He had been followed by outside pulmonologist who had 
reported stable “scarring” of his lungs. The patient endorses a history of asbestos exposure, 
as well as a history of being in industrial chemical salesman. He had a less than 5 pack year 
history of smoking and denied any exposure to pets, birds, hot tubs, or other antigens 
suggestive for hypersensitivity pneumonitis.  
Patient underwent extensive testing including high resolution CT scan, which revealed 
extensive upper and lower lobe fibrosis, focal atelectasis and pleural thickening at the left 
base, and extensive linear calcifications in both lungs associated with fibrosis. Comparing 
this study to a previous scan performed in 2002 the findings had progressed slightly. 
Pulmonary function testing was performed with spirometry showing a mixed pattern of 
obstruction and restriction, lung volumes consistent with mild restriction, and a mildly 
reduced DLCO (Table 1). Echocardiogram revealed normal left ventricular function, normal 
diastolic function, normal RV size and function, and indeterminate pulmonary pressures 
secondary to incomplete tricuspid regurgitant jet. Laboratory work was notable for negative 
hypersensitivity panel, fungal serologies, and normal blood counts. Patient underwent 
bronchoscopy for bronchoalveolar lavage and transbronchial biopsies. Cultures were 
negative and pathology of transbronchial biopsy revealed elastic fibrous tissue. Referral to 
cardiothoracic surgery was made for possible open lung biopsy however it was decided that 
the yield would be low given the extensive fibrotic changes and outweigh potential benefits. 
Patient was given a diagnosis of idiopathic pulmonary fibrosis and obstructive lung disease. 
Follow-up chest imaging and pulmonary function testing was planned. Bronchodilator 
therapy was offered, but refused by patient. 
In June of 2009 patient returned with no significant change in his symptoms. A repeat 
CT scan showed stable diffuse fibrotic changes. Pulmonary function testing was 
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performed and found to be essentially unchanged (Table 1). Given the relative stability 
of patient's symptoms and pulmonary function testing further follow-up was 
recommended. At this time, the patient inquired about treatment of his pulmonary 
fibrosis with stem cell therapy. Given the lack of safety and efficacy data in the use of 
stem cell therapy for the patient's disease, treatment with this modality was 
discouraged. 
In January 2010, under the oversight of Regenocyte Therapeutic, the patient underwent a 
bone marrow derived autologous stem cell infusion in the Dominican Republic. He reported 
that stem cells were infused into three different areas of each lung via a pulmonary artery 
catheter. Patient returned to Mayo Clinic in June 2010 for follow-up at which time he 
reported a significant subjective improvement in his symptoms of dyspnea on exertion. 
More specifically he states that immediately after the infusion he noted no change in 
Approximately 3 months after stem cell infusion, he professed to less dyspnea with exercise. 
For example, in the past it would take him approximately one hour to walk 2 miles and 
several months following stem cell therapy he was able to do so in one half hour. The 
patient's subjective improvements were unfortunately not correlated with any improvement 
in his pulmonary function testing (Table 1). CT imaging also remained unchanged showing 
stable diffuse fibrotic lung disease. 
5. Case 4 
5.1 Clinical history and course 
A 30-year-old man, originally from Albania who has lived in the United States for the past 
25 years, presented in June 2010 with a primary complaint of recurrent pneumonias. Patient 
had a history of repeated pneumonias since the age of 2. He had been hospitalized 
numerous times throughout his life secondary to pneumonia. He described outside 
evaluation as including bronchoscopy and nasal endoscopy with biopsy. Suspected 
diagnosis at time of consultation was primary ciliary dyskinesia. Medications at time of 
evaluation included fluticasone/salmeterol 250/50, tiotropium, and oxygen use nightly. 
Past medical history was otherwise negative. The patient has been a lifelong nonsmoker and 
denied any pulmonary family history. 
At Mayo Clinic, he underwent testing to further evaluate his history and suspected 
diagnosis of primary ciliary dyskinesia. CT Scan showed widespread hyperinflation with 
mosaic attenuation, bronchial wall thickening, and bronchiectasis. The distribution of this 
was diffuse and not lobar predominant. Pulmonary function testing revealed severe 
obstruction, hyperinflation, reduction in DLCO, and resting saturation of 86%. The patient 
was able to ambulate 255 meters on 6 minute walk with end-of-walk oxygen saturation 97% 
on 2 L nasal cannula (Table 1). Echocardiogram performed at time of evaluation revealed 
preserved left ventricular systolic and diastolic function, moderate to severe RV 
enlargement as well as decrease in RV systolic function. Right ventricular systolic pressure 
was estimated at 63 mmHg, with a Doppler derived MPAP of 45 mmHg.  The patient was 
diagnosed with severe obstructive lung disease secondary to bronchiectasis, with secondary 
PH (WHO group 3). Primary ciliary dyskinesia was suspected to be the underlying cause. 
Given the severity of patient's disease he was referred to lung transplantation for evaluation. 
In August of 2010 the patient returned for follow-up evaluation. About one month prior to 
this visit he underwent harvesting of stem cells from bone marrow and subsequent infusion 
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into his pulmonary arteries for treatment of pulmonary hypertension under the direction of 
Regenocyte Therapeutic. Further details of the procedure were not available at the time of 
visit. He did report subjective improvements in cough, improved energy level, and 
decreased utilization of oxygen. He also denied any exacerbations of his bronchiectasis in 
the interim. Repeat pulmonary function testing showed unchanged lung volumes, persistent 
severe obstruction and reduction in DLCO. Interestingly the patient had an improvement in 
his resting oxygen saturation to 92% from previous measure of 86%. 6 minute walk also 
showed an improvement, with patient walking of 341 meters compared to 255 meters, with 
an end-of-walk oxygen saturation of 90% on 2 L nasal cannula (Table 1). Echocardiography 
continued to show preserved left ventricular function with slight improvement in patient's 
RV enlargement as well as right ventricular systolic function. Estimated RVSP was reduced 
to 49 mmHg with a Doppler derived MPAP of 35 mmHg. 
The patient was evaluated by the lung transplantation service; however, he was not 
interested in proceeding given the subjective improvement he had experienced with his 
initial stem cell therapy.  
6. Discussion 
Use of stem cell therapy for the treatment of pulmonary diseases is gaining increasing 
attention. In the past decade, circulating bone marrow–derived cells similar to embryonal 
angioblasts have been identified (Asahara 1997) termed ‘‘endothelial progenitor cells 
(EPC).’’ These cells have the potential to proliferate and differentiate into mature endothelial 
cells. Two major types of these cells in human peripheral blood have been termed “early 
EPC’s” and “late outgrowth EPC’s,” both of which appear to have potential in lung 
microvascular repair and restoring vascular structures of the lung. (Yoon 2005) 
A number of trials are currently underway to evaluate the safety and effectiveness of the 
infusion of stem cells in pulmonary disease. A recently published report out of Brazil 
suggested both safety and improvement in quality of life in patients with severe 
COPD/emphysema (Ribeiro-Paes 2011). An ongoing multi-center trial is currently looking 
at the efficacy of  PROCHYMAL™ (ex Vivo Cultured Adult Human Mesenchymal Stem 
Cells) intravenous infusion for treatment of moderate to severe COPD. A pilot trial of 
autologous EPC administration for idiopathic pulmonary arterial hypertension was 
conducted at Zhejiang University, Hangzhou, China. The trial was a 12 week follow-up of 
patients after systemic administration of autologous EPC’s plus conventional therapy 
compared with patients receiving conventional therapy alone. (Wang 2007)  The results 
included increased six-minute-walk capacity and improved hemodynamic variables, 
including MPAP, pulmonary vascular resistance, and cardiac output. No concerns with the 
safety of the administration of EPC’s were encountered. The Pulmonary Hypertension and 
Cell Therapy (PHACeT) trial by the University of Toronto reported on the administration of 
autologous EPCs transduced to express exogenous nitric oxide synthase. Three patients in 
their initial panel showed a remarkable (nearly 50%) reduction in total pulmonary vascular 
resistance over the course of the 3-day delivery period. Subsequent study in additional 
patients is currently underway. (Weiss 2008) 
In our report, we present four patients who had peripherally harvested autologous stem 
cells infused into the pulmonary arteries. The procedure was not endorsed by or performed 
by Mayo Clinic. In addition, it was not performed in the context of an approved clinical trial. 
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The procedures were performed by Regenocyte Therapeutic. The reported infusion occurred 
at the Centro Otorrino Laringologia Hospital in Santo Domingo, Dominican Republic, as the 
procedure is not approved by the United States Food and Drug Administration.  
A variety of unusual challenges are illustrated by the care and interaction of these four 
patients at Mayo Clinic (Table 4). The inability to control for concomitant therapy 
complicates the interpretation of these patients’ clincial course both pre and post stem cell 
infusion. The first patient (Case 1) reported significant subjective improvement. At the 
time of follow-up many of these improvements had waned; however, there may have 
been mild improvement in both his resting pulmonary pressures by ECHO and 6MWT. 
(Table 2) These reductions in MPAP appeared to be sustained up to 24 months post 
infusion. Unfortunately, these functional and hemodynamic improvements did not 
translate into any significant change in the severe hypoxemia. Case 2 did not have any 
change in his symptoms or WHO functional class. He continued to have increasing 
supplemental oxygen requirements. His six-minute walk distance had slightly improved, 
and his ECHO demonstrated improved RV function.  Case 3 reported significant 
subjective improvement in exercise capacity. Objectively this did not translate into any 
improvement in PFT. Case 4 perhaps seemed to have the most significant improvement in 
objective measures including improvement in resting saturation, six minute walk distance 
and reduction in MPAP as estimated by ECHO.  
Are any of the changes due to the stem cell infusion?  It is impossible to determine in an 
uncontrolled setting. The role of multiple ongoing therapies and the limitations of the 
clinical assessments are particularly challenging to evaluate. Three of the four patients were 
on multiple therapies for treatment of PH and/or COPD at the time they received the stem 
cell infusion. Variations in oxygen requirements and supplementation may be particularly 
confounding since three of the four patients had obstructive lung disease with associated 
PH. Although validated surrogate endpoints in assessing response to therapy remain a 
source of ongoing discussion, measurements such as spirometry, ECHO, six minute walk 
distance, WHO functional class have been validated to monitor disease course, but remain 
imperfect. (Hoeper 2005; Snow 2007; Aduen 2009) 
If there were some benefit, it is unfortunate that it will remain inconclusive. Cases 1 and 3 
had subjective improvement; however, there clinical scenario was complex as outlined 
above. Case 4’s objective improvements are interesting but may represent concomitant 
therapies not disclosed in this uncontrolled setting. These cases present several challenging 
dilemmas for the clinician in this evolving area of science. Short of lung transplantation, 
there are generally no cures for the underlying pulmonary disease. In Cases 1, 3, and 4, we 
informed the patients that the only proven therapy for COPD/IPF in the setting of hypoxia 
was oxygen therapy. (Nocturnal Oxygen Therapy Trial Group 1980; Medical Research 
Council 1981)  Nonetheless, these patients had a difficult time accepting more conventional 
treatment and instead sought experimental therapies.  
The stem cell therapy raised the issue of unproven therapies to a new level as the patients 
personally paid approximately $50,000 for the therapy that was administered outside the 
context of either a clinical or research setting. In addition, the therapy was pursued 
independently of our clinical recommendation or oversight. Also of interest in these 
particular cases, was the potential impact on the relationship between the physician and 
patient since the patients had pursued an unendorsed experimental therapy outside the 
www.intechopen.com
 
New Advances in Stem Cell Transplantation 
 
514 
country. Although our stance on the experimental nature of stem cell therapy for 
pulmonary disease has always been clear, all of these patients researched, pursued and 
financed the therapy on their own accord. The clinician must be prepared for any 
potential conflict that may ensue if the patient seeks an experimental, unapproved 
therapy. In our practice, we maintain that such therapy should only be administered in 
the context of an approved research protocol.  Nonetheless, we felt committed to the 
ongoing management of these patients regardless of their decision to seek unapproved 
stem cell infusion therapy. 
 
Patient-Centered Provider-Centered Knowledge-Centered 
End-stage disease generates 
desperate interest in 
unproven therapies 
Limited time to discuss 
and counsel patients 
regarding unproven 
therapies 
Conventional therapies are 
often of limited value in 
severe pulmonary disease 
Patients may have strong 
desire to receive unproven 
therapies regardless of 
consequences 
Brief, simplistic cautionary 
advice may be insufficient 
to dissuade the patient 
from seeking unproven 
therapy 
Knowledge gap exists by 
definition with unproven 
therapies 
Inability to distinguish 
between for-profit endeavors 
and academically-based 
clinical trials 
Assessment of ethical, 
legal and professional 
nature of extra-mural 
practices often complex 
Provision of unproven 
therapy in uncontrolled 
(non-research) manner 
precludes firm conclusions 
from results 
Patient desires to maintain 
relationship with primary 
physician and to seek 
unconventional and/or 
unproven therapies 
Physician must maintain 
objectivity as well as 
primary role as patient 
advocate and caregiver 
Cooperative interaction 
and research between 
academic centers required 
to advance the science 
Legend:  Important challenges and limitations encountered in this series of 4 patients receiving stem cell 
infusion independent of your care. 
Table 4. Illustrative Lessons 
7. Conclusion 
Stem cell therapy has emerged as an experimental therapy to potentially treat a number of 
diseases, including pulmonary disorders. Current ongoing safety and efficacy trials will 
likely add significantly to our current understanding of the field, with hopes of aiding in 
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future patient care. In a parallel fashion, patients are pursuing this form of therapy 
outside of controlled research trials. Such practices create significant challenges in 
evaluating efficacy and potentially stress the provider-patient relationship in unique ways 
(Table 4). 
8. References 
Aduen JF, Castello R, Lazano MM, et al. An alternative echocardiographic method to 
estimate mean pulmonary artery pressure: diagnostic and clinical implications. J 
Am Soc Echocardiography 2009; 22:814-19. 
Alp S, Skrygan M, Schmidt WE, et al. Sildenafil improves hemodynamic parameters in 
COPD—an investigation of six patients. Pulm Pharmacol Ther 2006; 19:386– 
390. 
Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells 
for angiogenesis. Science 1997;275:964–967. 
Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination 
therapy for pulmonary arterial hypertension. Eur Respir J. 2005; 26:858- 
863.  
Jais X, D’Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic 
thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in 
iNopErable Forms of chronic Thromboembolic pulmonary hypertension), a 
randomized, placebo-controlled trial. J Am Coll Cardiol 2008;52:2127-34. 
Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in 
hypoxemic chronic obstructive lung disease: a clinical trial. Annals of Internal 
Medicine 1980;93(3):391-8.  
Reichenberger F, Voswinckel R, Enke B, et al. Long-term treatment with sildenafil in chronic 
thromboembolic pulmonary hypertension. Eur Respir J 2007;30: 922-7 
Report of the Medical Research Council Working Party. Long-term domiciliary oxygen 
therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and 
emphysema. Lancet 1981;1:681-5.  
Ribeiro-Paes JT, Bilaqui A, et al. Unicentric study of cell therapy in COPD/Pulmonary 
Emphysema. International Journal of COPD. 2011;6:63-71. 
Simmoneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary 
hypertension. J Am Coll Cardiol 2009; 54:S43-54. 
Snow JL and Kawut SM. Surrogate end points in pulmonary arterial hypertension:  
assessing the response to therapy. Clin Chest Med 2007; 28:75-89. 
Wang XX, Zhang FR, Shang YP, et al. Transplantation of autologous endothelial 
progenitor cells may be beneficial in patients with idiopathic pulmonary 
arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol. 
2007;49:1566–1571. 
Weiss DJ, Kolls JK, Ortiz LA, Panoskaltsis-Mortari A, Prockop DJ. Stem cells and cell 
therapies in lung biology and lung diseases. Proc Am Thorac Soc. 2008 Jul 
15;5(5):637-67. 
Yoon CH, Hur J, Park KW, et al. Synergistic neovascularization by mixed transplantation of 
early endothelial progenitor cells and late outgrowth endothelial cells: the role of 
www.intechopen.com
 
New Advances in Stem Cell Transplantation 
 
516 
angiogenic cytokines and matrix metalloproteinases. Circulation 2005;112:1618–
1627. 
www.intechopen.com
New Advances in Stem Cell Transplantation
Edited by Prof. Taner Demirer
ISBN 978-953-51-0013-3
Hard cover, 582 pages
Publisher InTech
Published online 24, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book documents the increased number of stem cell-related research, clinical applications, and views for
the future. The book covers a wide range of issues in cell-based therapy and regenerative medicine, and
includes clinical and preclinical chapters from the respected authors involved with stem cell studies and
research from around the world. It complements and extends the basics of stem cell physiology, hematopoietic
stem cells, issues related to clinical problems, tissue typing, cryopreservation, dendritic cells, mesenchymal
cells, neuroscience, endovascular cells and other tissues. In addition, tissue engineering that employs novel
methods with stem cells is explored. Clearly, the continued use of biomedical engineering will depend heavily
on stem cells, and this book is well positioned to provide comprehensive coverage of these developments.
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